Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Zolbetuximab

Generic Name: Zolbetuximab

Brand Names: Vyloy

Drug Type: Biotech

CAS Number: 1496553-00-4

Unique Ingredient Identifier: TF5MPQ8WGY

Overview

Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).

Background

Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Phase 2

Not yet recruiting

Posted: 2025/05/08

Sponsor:Universitaire Zieken...

ID:NCT06962137

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Recruiting

Posted: 2025/03/30

Sponsor:Astellas Pharma Kore...

ID:NCT06902545

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Phase 3

Not yet recruiting

Posted: 2025/03/30

Sponsor:Astellas Pharma Glob...

ID:NCT06901531

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2

Not yet recruiting

Posted: 2025/03/18

Sponsor:China Medical Univer...

ID:NCT06881017

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients with Locally Advanced Gastric Cancer

Phase 1

Not yet recruiting

Posted: 2024/12/13

Sponsor:Asan Medical Center

ID:NCT06732856

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

VYLOY™ POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL

Manufacturer:Baxter Oncology GmbH

Form:INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength:100mg/vial

Online:Yes

Approved: 2025/03/06

Approval:SIN17197P

Related News

Lunit Presents 12 AI-Powered Studies at ASCO 2025, Demonstrating Enhanced Cancer Treatment Selection

a day ago

Lunit will present 12 studies at ASCO 2025 showcasing AI-powered digital pathology solutions for precision oncology applications.

Vyloy Leads Claudin 18.2 Targeted Therapy Revolution with 60+ Drug Candidates in Pipeline

5 days ago

Vyloy (zolbetuximab) has emerged as the first approved Claudin 18.2-targeted therapy for HER2-negative gastric and gastroesophageal junction adenocarcinoma, marking a significant milestone in precision oncology.

Astellas to Present New Long-Term Survival Data for Cancer Therapies at ASCO 2025

8 days ago

Astellas will showcase 16 abstracts at the 2025 ASCO Annual Meeting, including two oral presentations highlighting long-term survival data for its oncology portfolio.

Global Pharma Launch Trends 2024: APAC Markets Gain Ground as Innovation Hubs

3 months ago

Analysis of 33 innovative drugs launched in 2024 reveals shifting market dynamics, with South Korea and Japan emerging as early-launch destinations alongside traditional markets like the US.

FDA Grants Priority Review to Astellas' Zolbetuximab for Gastric and GEJ Adenocarcinoma

5 months ago

The FDA has granted Priority Review to Astellas' Biologics License Application (BLA) for zolbetuximab, a Claudin 18.2-targeted monoclonal antibody.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy